SORIANO JOHN
Known title: Chief Compliance OfficerCIK: 0001740947
Associated companies
Transaction History
| INSM | ▲ Buy | Option Exercise | 17,349 | $241K | 9/7/2021 | View on chart |
| INSM | ▼ Sell | Open Market | 17,349 | $489K | 9/7/2021 | View on chart |
| INSM | ▲ Buy | Option Exercise | 17,349 | $241K | 9/7/2021 | View on chart |
| INSM | ▼ Sell | Open Market | 17,349 | $489K | 9/7/2021 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Wolfe Research Downgrades Insmed to Peer Perform Ahead of CHEST 2026
Wolfe Research lowered its rating on Insmed to Peer Perform, joining a wave of recent analyst downgrades. This move comes as the company prepares to present new data for its respiratory portfolio, including the Phase 3 PALM program, at the CHEST 2026 conference. While the stock is currently trading near its 52-week low, other analysts like HC Wainwright remain bullish with a $220 price target.
Wolfe Research Downgrades Insmed to Peer Perform Ahead of CHEST 2026. Wolfe Research lowered its rating on Insmed to Peer Perform, joining a wave of recent analyst downgrades. This move comes as the company prepares to present new data for its respiratory portfolio, including the Phase 3 PALM program, at the CHEST 2026 conference. While the stock is currently trading near its 52-week low, other analysts like HC Wainwright remain bullish with a $220 price target.